The Rationale: Last Reported Quarter and Management Outlook for Kartoon Studios Inc. (NYSEAMERICAN:TOON)
Key HighlightsTotal US householdDebtrose USD 334 billion, or 1.8%, to about USD 19.1 trillion in the third quarter of 2026, and was USD 520 billion higher than a year earlier.Mortgage balances increased USD 257 billion to about USD 13.4 trillion, and homeEquityline balances posted …
The Rationale: Last Reported Quarter and Management Outlook for Bragg Gaming Group Inc. (NASDAQ:BRAG)
Key HighlightsThird quarter 2026Revenuewas USD 320.7 million, up about 89% year over year and 40% from the second quarter, andGross Profitturned positive at USD 10.8 million, a 3.4% margin.Net loss was USD 125.5 million, or USD 0.46 per share, including USD 125.8 million ofDepreciationand …
The initial reaction was negative. Shares of Rocket Lab (NASDAQ:RKLB) fell about 6.7% after hours on November 9 as investors focused on the net loss of USD 79.7 million, or USD 0.12 per share, which was wider than expected and included a USD 27.3 …
Key HighlightsNet income for fiscal 2026 fell to USD 1.0 million from USD 56.0 million, leaving a diluted loss of USD 0.37 per common share againstEarningsof USD 0.13 a year earlier.Net service revenues rose 1.5% to USD 2,712.6 million, as snow removal added USD …
The Rationale: Last Reported Quarter and Management Outlook for American Strategic Investment Co. (NYSE:NYC)
Key HighlightsDigital Turbine (NASDAQ:APPS) closed down 35.84% on November 10, 2026, one of the largest declines in the US market that week.Fiscal second quarter 2027Revenuerose 27% to USD 178.7 million, well above market expectations of about USD 166.75 million.The company raised fiscal 2027 revenue …
Research and development expense fell to USD 2.3 million, mainly because nonclinical and clinical-trial costs dropped by USD 1.4 million after enrollment in the KOURAGE kidney injury study was paused in January 2026. The company said an independent committee flagged a mortality imbalance but …
The Rationale: Last Reported Quarter and Management Outlook for Tvardi Therapeutics, Inc. (NASDAQ:TVRD)